AVBP | ArriVent BioPharma, Inc. Common Stock Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	25.23 - 26.69
52 Week Range	14.35 - 36.37
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	614,817
Average Volume	155,896
Shares Outstanding	33,697,163
Market Cap	879,158,983
Sector	Healthcare
Industry	Biotechnology
IPO Date	2024-01-26

Valuation
Profitability
Growth
Health
P/E Ratio	-10.00
Forward P/E Ratio	N/A
EPS	-2.61
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	40
Country	USA
Website	AVBP

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. It also engages in the development and commercialization of targeted cancer therapies for non-small-cell lung cancer (NSCLC) and other solid tumors. The company develops Furmonertinib, an epidermal growth factor receptor mutant-selective tyrosine kinase inhibitor that is in phase 3 clinical trial for the treatment of NSCLC patients; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

*Chart delayed

Analyzing fundamentals for AVBP we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is very weak. For more detailed analysis please see AVBP Fundamentals page.

Watching at AVBP technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on AVBP Technicals page.